medigraphic.com

2013, Número 1

<< Anterior Siguiente >>

Rev Mex Med Repro 2013; 5.6 (1)


¿Tratar o no tratar? El efecto del tratamiento médico en parejas con pérdida gestacional recurrente idiopática: ¿qué dice la evidencia científica y la experiencia clínica?

Luna RRM, Vela AG, Cervantes E, Vergara JAM, Batiza RVA, Colín NJJS

Idioma: Español
Referencias bibliográficas: 38
Paginas: 9-17
Archivo PDF: 250.45 Kb.


FRAGMENTO

La pérdida gestacional o aborto recurrente es, sin duda, uno de los padecimientos más desgastantes y difíciles de manejar para el médico especialista en medicina reproductiva. La falta de evidencia científica para explicar la compleja fisiopatología del evento, así como la ausencia de estudios prospectivos y con distribución al azar que justifiquen algún tratamiento específico, son las principales causas del abuso de tratamientos injustificados


REFERENCIAS (EN ESTE ARTÍCULO)

  1. The Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril 2012;98:1103-1111.

  2. Jacobs PA, Hassold T. Chromosome abnormalities: origin and etiology in abortion and livebirths. In: Vogel F, Sperling K, editors. Human Genetics. New York: Springer-Verlag, 1987.

  3. Stirrat GM. Recurrent miscarriage. Lancet 1990:336:673- 675.

  4. Quenby SM, Farquharson RG. Predicting recurrent miscarriage: what is important? Obstet Gynecol 1993;82:132-138.

  5. Tang A, Quenby S. Recent thoughts on management and prevention of recurrent early pregnancy loss. Curr Opin Obstet Gynecol 2010;22:446-451.

  6. Stephenson MD, Sierra S. Reproductive outcomes in recurrent pregnancy loss associated with a parental carrier of structural chromosome rearrangement. Hum Reprod 2006;21:1076-1082.

  7. Saravelos SH, Cocksedge KA, Li TC. Prevalence and diagnosis of congenital uterine anomalies in women with reproductive failure: a critical appraisal. Hum Reprod Update 2008;14:415-429.

  8. Greaves M, Cohen H, Machin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipod syndrome. Br J Haematol 2000;109;704-715.

  9. Rey E, Kahn SR, David M, Shrier I. Trombophilic disorders and fetal loss: a meta-analysis. Lancet 2003;361:901-908.

  10. Bansal AS. Joining the immunological dots in recurrent miscarriage. Am J Reprod Immunol 2010;64:307-315.

  11. Arredondo F, Noble LS. Endocrinology of recurrent pregnancy loss. Semin Reprod Med 2006;24:33-39.

  12. Christiansen OB, Nybo Andersen A, Bosch E, Daya S, et al. Evidence-based investigations and treatments of recurrent pregnancy loss. Fertil Steril 2005;83:821-839.

  13. Stray-Pedersen B, Stray-Pedersen S. Etiologic factors and subsequent reproductive performance in 195 couples with a prior history of habitual abortion. Am J Obstet Gynecol 1984;148:433-440.

  14. Brigham SA, Conlon C, Farquharson RG. A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage. Hum Reprod 1999;14:2868-2871.

  15. Lindbohm ML, Sallmen M, Taskinen H. Effects of exposure to environmental tobacco smoke on reproductive health. Scand J Work Environ Health 2002;28:84-86.

  16. Ness RB, Grisso JA, Hirshinger N, Markovic N, et al. Cocaine and tobacco use and the risk of spontaneous abortion. N Engl J Med 1999;340:333-339.

  17. Kesmodel U, Wisborg K, Olsen SF, Henriksen TB, Secher NJ. Moderate alcohol intake in pregnancy and the risk of spontaneous abortion. Alcohol 2002;37:435-444.

  18. Boots C, Stephenson MD. Does obesity increase the risk of miscarriage in spontaneous conception: a systemic review. Semin Reprod Med 2011;29:507-513.

  19. Royal Collage of Obstetricians and Gynaecologists. The investigation and treatment of couples with recurrent first trimester and second trimester miscarriage. 2011. http:// www.rcog.org.uk

  20. Kaandorp SP, Goddijn M, van der Post JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010;362:1586-1596.

  21. Kaandrop S, di Nisio M, Goddijn M, Middeldrop S. Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. Cochrane Database Syst Rev 2009:CD 004734.

  22. Mantha S, Bauer KA, Zwicker JL. Low molecular weight heparin to achieve live birth following unexplained pregnancy loss: a systemic review. J Thromb Haemost 2010;8:263- 268.

  23. Clark P, Walker ID, Langhorne P, et al. SPIN (Scottish Pregnancy Intervention) Study: a multicenter, randomized controlled trial of low-molecular-weight-heparin and low dose aspirin in women with recurrent miscarriage. Blood 2010;115:4162-4167.

  24. Haas DM, Ramsey PS. Progestogen for preventive miscarriage. Cochrane Database Syst Rev 2008:CD003511.

  25. Porter TF, La Cursiere Y, Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev 2006:CD 000112.

  26. Carrell DT, Liu L, Peterson CM, Jones KP, et al. Sperm DNA fragmentation is increased in couples with unexplained recurrent pregnancy loss. Arch Androl 2003;49:49-55.

  27. Benchaib M, Lornage J, Mazoyer C, Lejeune H, et al. Sperm deoxyribonucleic acid fragmentation as a prognostic indicator of assisted reproductive technology outcome. Fertil Steril 2007;87:93-100.

  28. Fischer J, Colls P, Escudero T, Munne S. Preimplantation genetic diagnosis (PGD) improves pregnancy outcome for translocation carriers with a history of recurrent losses. Fertil Steril 2010;94:283-289.

  29. Bashiri A, Gete S, Mazor M, Gete M. Recurrent pregnancy loss-evaluation and treatment. Review. Harefuah 2011;151:852-856.

  30. Shapirta E, Ratzon R, Shoham-Vardi I, Serjienko R, et al. Primary vs secondary recurrent pregnancy loss –epidemiologic outcome. J Perinat Med. 2012;40:389-396.

  31. Bashiri A, Ratzon R, Amar S, Serjienko R, et al. Two vs three or more primary recurrent pregnancy losses-are there any differences in epidemiologic characteristics and index pregnancy outcome? J Perinat Med 2012;40:365-371.

  32. Stern JJ, Dorfmann AD, Gutierrez Najar AJ, Cerrillo M, Coulam CB. Frequency of abnormal karyotypes among abortuses from women with and without a history of recurrent spontaneous abortion. Fertil Steril 1996;65:250-253.

  33. Clark DA. The power of observation. Am J Reprod Immunol 2011;66:71-75.

  34. Coulam CB, Krysa L, Stern JJ, Bustillo M. Intravenous immunoglobulin for treatment of recurrent pregnancy loss. Am J Reprod Immunol 1995;34:333-337.

  35. Ticconi C, Giuliani E, Veglia M, Pietropolli A, et al. Thyroid autoimmunity and recurrent miscarriage. Am J Reprod Immunol 2011;66:452-459.

  36. Winger EE, Reed JL, Ashoush S, El-Toukhy T, et al. Preconception CD56+16+ adn/or Th1:Th2 levels predict benefit from IVIG therapy in subfertile women undergoing IVF. Am J Reprod Immunol 2011;66:394-403.

  37. Moraru M, Carbone J, Alecsandru D, Castillo-Rama M, Sanchez Ramon S. Intravenous immunoglobulin treatment increased live birth rate in a Spanish cohort of women with recurrent reproductive failure and expanded CD56+ cells. Am J Reprod Immunol 2012;68:75-84.

  38. Coulam CB, Stern JJ. Ultrasonographic findings of pregnancy loss after treatment for recurrent pregnancy loss: intravenous immunoglobulin versus placebo. Fertil Steril 1994;61:248-251.




2020     |     www.medigraphic.com